Several major healthcare systems are creating their own AI-driven chatbots to help clinicians more easily access and navigate patient health records.
Scientists have developed an AI system that analyzes clinical notes to identify patients who may be at risk of cognitive decline, enabling healthcare providers to intervene earlier.
More than 60 healthcare organizations have jointly requested that national health record exchanges enhance protections to block unauthorized access to patient information by malicious parties.
In this edition of AI Prognosis, we highlight the most significant health AI developments that have emerged in the past month, setting the stage for innovation and change in 2026.
Bob Nelsen, a renowned venture capitalist, is spearheading a groundbreaking AI venture that he predicts will rank among the world's most influential companies. This secretive project, dubbed Prometheus, marks a significant expansion of Nelsen's interests beyond the healthcare sector, highlighting his confidence in artificial intelligence's transformative potential.
AI chatbot developers are increasingly offering health advice directly to consumers. This shift raises important questions about the accuracy and safety of AI-generated medical guidance.
Artificial intelligence has reached a pivotal milestone by successfully creating drug-like antibodies, signaling a potential transformation in the biopharmaceutical industry. This breakthrough prompts the question: how soon will AI-driven antibody design revolutionize drug development and biopharma practices?
As 2026 approaches, the health care sector prepares for critical discussions on financing clinical AI. Industry stakeholders face important decisions about payment models that will shape the future of AI integration in medical treatment.
Doctors are overwhelmed by the sheer volume of new medical research, making it difficult to stay fully informed. Meanwhile, patients are increasingly turning to AI tools for health insights. It's time for medical professionals to adopt AI as a valuable resource to enhance their practice and deliver better care.
The FDA has granted approval for the oral formulation of Novo Nordisk’s Wegovy, originally an injectable treatment for weight management. This marks the first approval of a GLP-1 receptor agonist in pill form for obesity treatment, potentially broadening patient access to this therapy.